Tag: BLT

Benitec Biopharma ASX BLT licensing deal Axovant Sciences oculopharyngeal muscular dystrophy drug

Benitec Biopharma secures multimillion-dollar licensing deal with Axovant Sciences

Biopharmaceutical company Benitec Biopharma (ASX: BLT) has decided to licence exclusive global rights to its proprietary oculopharyngeal muscular dystrophy drug AXO-AAV-OPMD to Axovant Sciences. The licensing deal...
Benitec Biopharma ASX BLT Russia oncology study Phase 2

Benitec Biopharma receives Russian regulatory approval for oncology study

Biopharmaceutical company Benitec Biopharma (ASX: BLT) is well on its way to generating clinical trial results for its potentially ground-breaking treatment of head and...
Benitec Biopharma ASX BLT FDA orphan drug oculopharyngeal muscular dystrophy

Benitec’s BB-301 muscular dystrophy drug granted FDA orphan status

Benitec Biopharma (ASX: BLT) has received orphan drug designation from the FDA for its BB-301 which has been created to treat oculopharyngeal muscular dystrophy. The...
Benitec Biopharma BLT ASX US patent hepatitis B treatment

Benitec Biopharma secures US patent for hepatitis B treatment

Biotechnology company Benitec Biopharma (ASX: BLT) has secured a US patent for its hepatitis B treatment, which, if successfully developed, could provide a “functional...